We are a highly collaborative organisation, with data services run in partnership with organisations throughout the world, international research projects of global significance and joint initiatives with companies of all sizes. We are a partner in several of Europe’s emerging research infrastructures, and host the Hub of ELIXIR, Europe's distributed infrastructure for life-science information.
Public health research
We are a partner in COMPARE, an international collaboration to speed up the detection of and response to infectious disease outbreaks using genome technology. By providing compute and data-sharing infrastructure, we make it possible for clinical, risk-assessment and research professionals to access, analyse and compare crucial information in real time. We are also a partner in the ZIKAlliance, a multinational endeavour that investigates clinical, fundamental, environmental and social aspects of ZIKV infection. We help coordinate molecular data for this crucial project, which focuses on pregnant women, environmental factors and epidemiology.
The Global Alliance for Genomics and Health (GA4GH) is a global effort to accelerate medical and research advancements through the responsible sharing of genomic and clinical data. GA4GH, Chaired by EMBL-EBI Director Ewan Birney, counts over 300 members from the public and private sector.
EMBL-EBI manages data for the International Mouse Phenotyping Consortium (IMPC), which promotes replacement, reduction and refinement in animal research. The IMPC’s goal is to determine the functions of some 20,000 genes common to mice and humans by systematically knocking out protein-coding genes in the mouse and assessing the physiological characteristics associated with each one. EMBL-EBI, in collaboration with MRC Harwell and the Wellcome Trust Sanger Institute, delivers IMPC informatics.
Open Targets is transforming the way scientists find, validate and prioritise drug targets. It blends the expertise of world-leading organisations including GSK, EMBL-EBI, Biogen and the Wellcome Trust Sanger Institute to identify and validate the causal links between targets, pathways and diseases. Open Targets welcomes new partners who share its vision.
The Pan-Cancer Analysis of Whole Genomes (PCAWG) project undertakes whole-genome-sequencing, transcriptome, and DNA methylome profiling from 20 cancer types in 2500 patients. EMBL-EBI research activities include novel mutation identification methods, translation to the clinic as well as standardised integrative analyses of data generated in diverse contexts where sharing of raw patient genomic data is complicated or impossible.
Innovative Medicines Initiative projects
Our Industry Programme helps its partners and EMBL-EBI researchers establish collaborations in the context of the Innovative Medicines Initiative.
- EBiSC: European Bank for induced pluripotent Stem Cells
- EU-AIMS: A large-scale drug-discovery collaboration that brings together academic and industrial R&D with patient organisations to develop and assess novel treatment approaches for autism.
- EMIF: Developing a common information framework of patient-level data that will link up and facilitate access to diverse medical and research data sources.
- eTOX: Developing innovative in silico strategies and novel software tools to better predict the toxicological profiles of small molecules in early stages of the drug development pipeline.
- EMTRAIN: A platform for education and training covering the whole life cycle of medicines research, from basic science through clinical development to pharmacovigilance.
- DDMoRe: The Drug Disease Model Resources consortium: Developing a public drug and disease model library.
TransQST: Translational quantitative systems toxicology to improve the understanding of the safety of medicines